Walleye Capital
LGND icon

Walleye Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Walleye Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$537K Buy
+1,700
New +$401K ﹤0.01% 2657
2025
Q1 		– Sell
-3,500
Closed -$375K – 4717
2024
Q4 		$375K Buy
3,500
+3,400
+3,400% +$384K ﹤0.01% 3229
2024
Q3 		$10K Buy
+100
New +$10.1K ﹤0.01% 4913
2024
Q1 		– Sell
-8,800
Closed -$628K – 5663
2023
Q4 		$628K Buy
8,800
+7,500
+577% +$443K ﹤0.01% 2762
2023
Q3 		$77.9K Buy
+1,300
New +$85.6K ﹤0.01% 4042
2023
Q1 		– Sell
-100
Closed -$6.68K – 4174
2022
Q4 		$6.68K Sell
100
-60
-38% -$3.9K ﹤0.01% 2817
2022
Q3 		$9K Buy
+160
New +$9.41K ﹤0.01% 2834
2019
Q4 		– Sell
-20,839
Closed -$1.29M – 2049
2019
Q3 		$1.29M Sell
20,839
-5,931
-22% -$372K 0.08% 350
2019
Q2 		$1.91M Buy
+26,770
New +$1.97M 0.21% 103

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's LGND Position: Q2 2026 in Review

Walleye Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 10,333 shares — an estimated $2.43M sold.

Walleye Capital first reported a position in LGND in Q2 2022 and held it in 8 quarters. The position peaked at $2.06M in Q1 2026. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Walleye Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 10,333 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.43M.
  • Walleye Capital first reported a position in Ligand Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • Walleye Capital's Ligand Pharmaceuticals position peaked at $2.06M in Q1 2026.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.